An Exploratory Study on the Use of Ipalotinib (Tislelizumab) Combined With Sunitinib and Olaparib for Neoadjuvant Therapy in HRD-positive Advanced Ovarian Cancer
Clinical trial NCT07667751 · RECRUITING
Trial details
- NCT number
- NCT07667751
- Sponsor
- Bai-Rong Xia
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-06-01
- Primary completion
- 2027-12-31
- Enrollment
- 35
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.